# pulmonary arterial hypertension FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/pulmonary-arterial-hypertension

> 16 upcoming FDA catalysts in pulmonary arterial hypertension: treprostinil palmitil (INSM) on Dec 2026 to Mar 2027 (topline data readout); seralutinib (GOSS) on December 2026 (primary completion); seralutinib (GOSS) on Dec 2026 to Mar 2027 (topline data readout); treprostinil palmitil (INSM) on December 2026 (primary completion); and 12 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 10, 2025 | [INSMED Inc topline data readout](https://sec-api.dev/companies/insm/catalysts) | INSM | pulmonary arterial hypertension | completed, positive | "On June 10, 2025, the Company announced positive topline results from its Phase 2b TPIP PAH study, a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of TPIP administered once daily in patients with PAH (World Health" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1104506/000114036125022023/ef20050418_8k.htm)) |
| October 7, 2025 | [Opsumit (macitentan) primary completion](https://sec-api.dev/pdufa/macitentan) | JNJ | Pulmonary Arterial Hypertension | completed | "NCT04273945 (Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-07 (ACTUAL); Lead Sponsor Actelion." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04273945)) |
| November 20, 2025 | [WINREVAIR (sotatercept) primary completion](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Arterial Hypertension | completed | "NCT06664801 (A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-20 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06664801)) |
| September 9, 2026 | [Gb002 (seralutinib) primary completion](https://sec-api.dev/pdufa/gb002-seralutinib) | GOSS | Pulmonary Arterial Hypertension | withdrawn | "NCT04816604 (Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-09-09 (ACTUAL); Lead Sponsor Gossamer Bio USA, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04816604)) |
| September 23, 2026 | [Seralutinib NDA/BLA submission](https://sec-api.dev/pdufa/seralutinib) | GOSS | pulmonary arterial hypertension | completed | "On September 23, 2026, Gossamer Bio, Inc. (the "Company") announced that it submitted a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in September 2026 for seralutinib for the treatment of pulmonary arterial hypertension ("PAH")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000104/goss-20260923.htm)) |
| Dec 2026 to Mar 2027 | [Treprostinil palmitil topline data readout](https://sec-api.dev/pdufa/treprostinil-palmitil) | INSM | Pulmonary Arterial Hypertension | scheduled | "NCT05649748 (An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05649748)) |
| December 2026 | [Seralutinib primary completion](https://sec-api.dev/pdufa/seralutinib) | GOSS | Pulmonary Arterial Hypertension | scheduled | "NCT06274801 (Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Gossamer Bio USA, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06274801)) |
| Dec 2026 to Mar 2027 | [Seralutinib topline data readout](https://sec-api.dev/pdufa/seralutinib) | GOSS | Pulmonary Arterial Hypertension | scheduled | "NCT06274801 (Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Gossamer Bio USA, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06274801)) |
| December 2026 | [Treprostinil palmitil primary completion](https://sec-api.dev/pdufa/treprostinil-palmitil) | INSM | Pulmonary Arterial Hypertension | scheduled | "NCT05649748 (An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05649748)) |
| Jun to Sep 2028 | [WINREVAIR (sotatercept) topline data readout](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Arterial Hypertension | scheduled | "NCT06925750 (A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-06-16 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06925750)) |
| June 2028 | [WINREVAIR (sotatercept) primary completion](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Arterial Hypertension | scheduled | "NCT06925750 (A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-06-16 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06925750)) |
| Sep to Dec 2028 | [WINREVAIR (sotatercept) topline data readout](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Arterial Hypertension | scheduled | "NCT05587712 (Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-21 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05587712)) |
| September 2028 | [WINREVAIR (sotatercept) primary completion](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Arterial Hypertension | scheduled | "NCT05587712 (Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-21 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05587712)) |
| Dec 2028 to Mar 2029 | [WINREVAIR (sotatercept) topline data readout](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Arterial Hypertension | scheduled | "NCT07218029 (A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-12-07 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07218029)) |
| Dec 2028 to Mar 2029 | [Treprostinil palmitil inhalation powder topline data readout](https://sec-api.dev/pdufa/treprostinil-palmitil-inhalation-powder) | INSM | Pulmonary Arterial Hypertension | scheduled | "NCT07481981 (A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-28 (ESTIMATED); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07481981)) |
| December 2028 | [WINREVAIR (sotatercept) primary completion](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Arterial Hypertension | scheduled | "NCT07218029 (A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-12-07 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07218029)) |
| December 2028 | [Treprostinil palmitil inhalation powder primary completion](https://sec-api.dev/pdufa/treprostinil-palmitil-inhalation-powder) | INSM | Pulmonary Arterial Hypertension | scheduled | "NCT07481981 (A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-28 (ESTIMATED); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07481981)) |
| May to Aug 2029 | [WINREVAIR (sotatercept) topline data readout](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Arterial Hypertension | scheduled | "NCT07646860 (A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07646860)) |
| May 2029 | [WINREVAIR (sotatercept) primary completion](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Arterial Hypertension | scheduled | "NCT07646860 (A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07646860)) |
| June 2029 | [IKT-001 primary completion](https://sec-api.dev/pdufa/ikt-001) | IKT | Pulmonary Arterial Hypertension | scheduled | "NCT07365332 (An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Inhibikase Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07365332)) |
| Jun to Sep 2029 | [IKT-001 topline data readout](https://sec-api.dev/pdufa/ikt-001) | IKT | Pulmonary Arterial Hypertension | scheduled | "NCT07365332 (An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Inhibikase Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07365332)) |

## Drugs

- [Opsumit (macitentan)](https://sec-api.dev/pdufa/macitentan) (JNJ)
- [WINREVAIR (sotatercept)](https://sec-api.dev/pdufa/sotatercept) (MRK)
- [Gb002 (seralutinib)](https://sec-api.dev/pdufa/gb002-seralutinib) (GOSS)
- [Seralutinib](https://sec-api.dev/pdufa/seralutinib) (GOSS)
- [Treprostinil palmitil](https://sec-api.dev/pdufa/treprostinil-palmitil) (INSM)
- [Treprostinil palmitil inhalation powder](https://sec-api.dev/pdufa/treprostinil-palmitil-inhalation-powder) (INSM)
- [IKT-001](https://sec-api.dev/pdufa/ikt-001) (IKT)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/pulmonary-arterial-hypertension.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "pulmonary arterial hypertension FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/pulmonary-arterial-hypertension

```bibtex
@misc{secapidev_indications_pulmonary_arterial_hypertension_20261116,
  title        = {pulmonary arterial hypertension FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/pulmonary-arterial-hypertension}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_pulmonary_arterial_hypertension_20261116","title":"pulmonary arterial hypertension FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/pulmonary-arterial-hypertension","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
